Lipocine has launched its latest Phase 3 clinical trial of an experimental oral treatment for postpartum depression (PPD), dosing the first participant in a study designed to assess whether a 48-hour at-home treatment can deliver rapid relief to women battling the condition.

 

The study, named BLOOM (Brexanolone Lifting Outcomes of Moms), will evaluate LPCN 1154, an oral formulation of brexanolone being developed as a short-course treatment that women can take at home. The trial marks a fresh step in the company's efforts to advance the drug towards a potential New Drug Application (NDA) submission.

 

Lipocine expects to enrol approximately 120 participants in the placebo-controlled outpatient study, with topline results anticipated in the second half of 2027.

 

"Our goal is to develop a treatment that provides rapid symptom relief through a 48-hour oral course taken at home," said Mahesh Patel, President and Chief Executive Officer of Lipocine. "We believe the BLOOM Phase 3 study is designed to promote study enrollments that are representative of the actual patient population of postpartum depression and provide confidence in data quality."

 

However, the latest trial comes against the backdrop of a significant setback: Lipocine's previous Phase 3 study failed to meet its primary endpoint in the full analysis set. While safety outcomes and exploratory post hoc findings from that trial supported further investigation, the earlier results underscore the challenge facing the company's latest development effort.

 

BLOOM has been redesigned to incorporate lessons from the previous trial and feedback from the US Food and Drug Administration (FDA). The company has strengthened site selection, participant eligibility assessments and data-quality controls in an effort to improve trial execution and make the findings more reliable and interpretable.

 

These changes, however, are intended to strengthen the study's design and do not establish the drug's efficacy or guarantee a successful outcome.

 

BLOOM will evaluate the same 48-hour dosing regimen and primary efficacy endpoint used in the completed Phase 3 trial. The primary endpoint will measure the change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at 60 hours after treatment initiation.

 

The company is also tightening oversight of participating clinical sites. Measures include third-party support for site selection, broader geographic representation, participation by academic institutions, limits on the number of participants recruited at individual sites and periodic reviews of patient populations.

 

Sites with significant operational or data-quality concerns will be excluded from selection.

 

A key focus of the revised study design is reducing the potential for placebo response, a critical consideration in depression trials.

 

The protocol will use fewer rating scales and assessments, reduce participant contact with site staff, introduce centralised ratings for screening and eligibility, and standardise participant education on study procedures and assessments.

 

BLOOM will also include prespecified sensitivity analyses examining outlier clinical sites and pharmacokinetic data to assess the robustness of the eventual findings.

 

The study is intended to complement Lipocine's existing clinical data package and support a potential NDA filing through the FDA's 505(b)(2) regulatory pathway.

 

For Lipocine, the first participant dosing represents an important development milestone. But the ultimate test will be whether BLOOM can demonstrate meaningful efficacy and safety after the previous Phase 3 trial failed to achieve its primary objective.